Genitourinary Cancers

The FDA has granted a breakthrough therapy designation to erdafitinib for the treatment of metastatic urothelial carcinoma.

Parminder Singh, MD, discusses the potential of immunotherapy, the importance of sequencing to avoid disease progression, and the use of chemotherapy and radiation therapy to reach an unmet need in muscle-invasive bladder cancer.

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses PD-L1 data with pembrolizumab (Keytruda) in patients with bladder cancer.

Amit Gupta, MD, urologic oncologist, Department of Surgery, Cedars-Sinai Medical Center, discusses how the use of immunotherapy agents is altering the role of surgery in bladder cancer and the need for Bacillus Calmette-Guérin (BCG) alternatives.

James Wysock, MD, discusses the evolution of cytoreductive nephrectomy in renal cell carcinoma.